At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 41 enrolled
Drug / intervention
KAN-101 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1 Study of the Safety and Tolerability of Single and Multiple Doses of KAN-101 in Patients With Celiac Disease (ACeD)
Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA·interventional·Posted Jan 30, 2020·Updated Aug 6, 2024
In Brief
A Phase 1 clinical trial evaluating KAN-101 and Placebo for Celiac Disease. Completed, enrolled 41 participants across 13 sites.
Detailed Summary
A safety study of KAN-101 in patients with celiac disease. The study has two parts: 1. Part A - first in human study in which patients receive a single dose of KAN-101 2. Part B - patients will receive three doses of either KAN-101 or placebo
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCeliac Disease
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
2020202120222023202420252026
Enrollment StartJan 2020
First PostedJan 2020
Primary CompletionOct 2021
TodayJul 2026
First PostedJan 30, 2020
Enrollment StartJan 21, 2020
Primary CompletionOct 8, 2021
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 6.4 years ago
Interventions
KAN-101drug
Intravenous (IV) infusion
Placebodrug
Intravenous (IV) infusion